Products
Mesuximide is commercially available in the form of capsules (Petinutin). It has been approved in many countries since 1963.
Structure and properties
Mesuximide (C12H13NO2, Mr = 203.2 g/mol) belongs to the succinimides and exists as a racemate. The active metabolite -demethylmesuximide, with a long half-life of over 30 hours, is also involved in the effects.
Effects
Mesuximide (ATC N03AD03) has antiepileptic properties. It increases the response threshold in the central nervous system to seizure-inducing stimuli. The mechanism of action is not precisely known, and the active ingredient is insufficiently documented in the scientific literature, in our opinion.
Indications
- Psychomotor seizures (petit mal) in the setting of mixed epilepsies.
- Absences and psychomotor seizures (2nd line agents).
Dosage
According to the professional information. Treatment is started cautiously. Capsules are taken throughout the day and with meals.
Contraindications
- Hypersensitivity, including to other succinimides.
- Hepatic porphyria
- Hematological diseases
For complete precautions, see the drug label.
Interactions
Drug-drug interactions have been described with phenytoin, primidone, phenobarbital, felbamate, valproic acid, lamotrigine, ciclosporin, alcohol, and sleeping pills.
Adverse effects
The most common potential adverse effects include ataxia, dizziness, sleep disturbances, nausea, vomiting, and fatigue.
